NewAmsterdam Pharma Co N.V.
NAMS Nasdaq
SEC CIK 1936258
Follow NewAmsterdam Pharma
Weekly email: filings, results
Revenue, last quarter
$19.2M
+5406.9% vs same quarter last year
Net income
−$17.4M
+75.9% vs same quarter last year
EPS, diluted
−$0.14
+77% vs same quarter last year
Operating cash flow
−$39.8M
−21.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $22.5M | −$203M |
| FY24 | $45.6M | −$242M |
| FY23 | $14.1M | −$177M |
| FY22 | $102.7M | −$22.6M |
| FY21 | - | −$41.8M |
| FY20 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1002.9% | −902.1% |
| FY24 | −386.9% | −531.1% |
| FY23 | −1298.6% | −1256.2% |
| FY22 | −3.5% | −22% |
| FY21 | - | - |
| FY20 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$148M |
| FY24 | −$159.2M |
| FY23 | −$141.2M |
| FY22 | $10.4M |
| FY21 | −$29.5M |
| FY20 | - |
- NewAmsterdam Pharma
- Healthcare median
Show the numbers
| Year | NewAmsterdam Pharma | Healthcare median |
|---|---|---|
| FY25 | −902.1% | −30.6% |
| FY24 | −531.1% | −47% |
| FY23 | −1256.2% | −58% |
| FY22 | −22% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |